Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
Trial Summary
What is the purpose of this trial?
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as gemtuzumab ozogamicin, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well gemtuzumab ozogamicin works in treating young patients who are undergoing remission induction, intensification therapy, and allogeneic bone marrow transplant for newly diagnosed acute myeloid leukemia.
Research Team
Janet Franklin, MD, MPH
Principal Investigator
Children's Hospital Los Angeles
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- Allogeneic Bone Marrow Transplant (Bone Marrow Transplant)
- Gemtuzumab Ozogamicin (Monoclonal Antibodies)
- Intensification Therapy (Chemotherapy)
- Remission Induction Therapy (Chemotherapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Oncology Group
Lead Sponsor
Dr. Doug Hawkins
Children's Oncology Group
Chief Executive Officer since 2020
MD from University of Washington School of Medicine
Dr. Leo Mascarenhas
Children's Oncology Group
Chief Medical Officer since 2024
MD, MS from Cedars-Sinai Guerin Children’s
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School